IFNγ-IL-17-IL-22+CD4+ subset and IL-22-producing cells in tumor draining lymph nodes of patients with breast cancer.


Journal

Breast disease
ISSN: 1558-1551
Titre abrégé: Breast Dis
Pays: Netherlands
ID NLM: 8801277

Informations de publication

Date de publication:
2022
Historique:
entrez: 3 10 2022
pubmed: 4 10 2022
medline: 5 10 2022
Statut: ppublish

Résumé

A recently introduced CD4+ T subset that mainly secretes interleukin (IL-) 22 has been reported to be associated with a variety of tumors, including colon, gastric, hepatocellular, and small- and large-cell lung carcinoma. Both tumor-promoting and - suppressing roles have been suggested for these cells. In the present study, we aimed to investigate the frequency of IL-22-producing subsets in tumor-draining lymph nodes (TDLNs) of the patients with breast cancer and determine their association with the clinicopathological characterizations of the disease. Thirty untreated women diagnosed with breast cancer were enrolled and their axillary lymph nodes were dissected during surgery. Mononuclear cells were isolated using Ficoll density gradient, activated, permeabilized, and stained by fluorochrome-conjugated antibodies against CD4, IL-22, IL-17, and IFNγ. The cells were then acquired on the FACSCalibur flow cytometer, and raw data was analyzed by the FlowJo software package (V10). Our results demonstrated that 2.39% ± 0.39 of CD4+ lymphocytes in TDLNs of patients with breast cancer produced IL-22. Among them, 0.64% ± 0.8 just produced IL-22 but were negative for IFNγ and IL-17. Statistical analysis indicated that the frequency of CD4+IL-22+ cells was significantly higher in the patients with stage III and the ones with 3-9 tumor involved lymph nodes (N2) compared to those with stage II and those having 1-3 tumor involved lymph nodes (N1) (P = 0.008 and P = 0.004, respectively). The higher frequency of IL-22-producing cells in draining lymph nodes of patients with more advanced tumors (higher stage (stage III) and more involved lymph nodes) suggests a role for IL-22-producing cells in the tumor progression and invasion. However, further studies with larger sample size and more functional studies are needed to clarify the role of IL-22-producing cells in breast cancer pathogenesis.

Sections du résumé

BACKGROUND BACKGROUND
A recently introduced CD4+ T subset that mainly secretes interleukin (IL-) 22 has been reported to be associated with a variety of tumors, including colon, gastric, hepatocellular, and small- and large-cell lung carcinoma. Both tumor-promoting and - suppressing roles have been suggested for these cells. In the present study, we aimed to investigate the frequency of IL-22-producing subsets in tumor-draining lymph nodes (TDLNs) of the patients with breast cancer and determine their association with the clinicopathological characterizations of the disease.
METHODS METHODS
Thirty untreated women diagnosed with breast cancer were enrolled and their axillary lymph nodes were dissected during surgery. Mononuclear cells were isolated using Ficoll density gradient, activated, permeabilized, and stained by fluorochrome-conjugated antibodies against CD4, IL-22, IL-17, and IFNγ. The cells were then acquired on the FACSCalibur flow cytometer, and raw data was analyzed by the FlowJo software package (V10).
RESULTS RESULTS
Our results demonstrated that 2.39% ± 0.39 of CD4+ lymphocytes in TDLNs of patients with breast cancer produced IL-22. Among them, 0.64% ± 0.8 just produced IL-22 but were negative for IFNγ and IL-17. Statistical analysis indicated that the frequency of CD4+IL-22+ cells was significantly higher in the patients with stage III and the ones with 3-9 tumor involved lymph nodes (N2) compared to those with stage II and those having 1-3 tumor involved lymph nodes (N1) (P = 0.008 and P = 0.004, respectively).
CONCLUSION CONCLUSIONS
The higher frequency of IL-22-producing cells in draining lymph nodes of patients with more advanced tumors (higher stage (stage III) and more involved lymph nodes) suggests a role for IL-22-producing cells in the tumor progression and invasion. However, further studies with larger sample size and more functional studies are needed to clarify the role of IL-22-producing cells in breast cancer pathogenesis.

Identifiants

pubmed: 36189579
pii: BD210084
doi: 10.3233/BD-210084
doi:

Substances chimiques

Fluorescent Dyes 0
IFNG protein, human 0
Interleukin-17 0
Interleukins 0
Ficoll 25702-74-3
Interferon-gamma 82115-62-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

383-390

Auteurs

Ali Salmanpour (A)

Cancer Immunology and Immunotherapy Group, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran.

Somayeh Rezaeifard (S)

Cancer Immunology and Immunotherapy Group, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran.

Razie Kiani (R)

Cancer Immunology and Immunotherapy Group, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran.

Sedigheh Tahmasebi (S)

Department of Surgery, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Breast Disease Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Zahra Faghih (Z)

Cancer Immunology and Immunotherapy Group, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran.

Nasrollah Erfani (N)

Cancer Immunology and Immunotherapy Group, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH